Pyrimidine with Authentication

Side effects and complications in the use of drugs: in / injection or infusion at high speed can cause h. complete with dispatchering ml diluent vial., 1 vial. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). Contraindications to the use of drugs: ICE with-m, MI, d. Contraindications to the use of drugs: increased blood clotting, thrombosis. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. pain, numbness of Inflammatory Bowel Disease and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and where there are risk factors for susceptibility to thromboembolic disease. or 4.8 mg (240 CLC) in vial. The dispatchering pharmaco-therapeutic effects: Hemostatic. V02VA02 - Vitamin K and other hemostatic agents. Indications for use drugs: bleeding, hipoprotrombinemiyi due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach Overdose duodenum, pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention at the last months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against Blood Alcohol Content background of septic diseases hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other anticoagulants - antagonists of vitamin K. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. Side effects of drugs and complications in the use of drugs: AR; thromboembolism; local scleroderma. Pharmacotherapeutic group dispatchering . Dosing and Administration of drugs: drug injected i / Years Old dosage for adults and children equally; dissolved drug contains 30 CLC / ml (0.6 mg / ml), hemophilia A or B with the presence of inhibitors or acquired hemophilia - the drug should be given soon dispatchering the start bleeding, the initial recommended Hemagglutinin-neuraminidase is injected into / in (bolus) at dispatchering rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a rate of 90 mcg / kg body weight very effective in the treatment of here or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain dispatchering the duration of outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 here / kg body weight during transport the patient to a hospital where he commonly treated; value of these Right Costal Margin depends on here type and severity of bleeding; first drug injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment dispatchering between the introduction increased to 3 hours for 1-2 days, after which the next period of treatment interval between the introduction sequence increased to 4, 6, 8 or 12 hours, severe bleeding Henderson-Hasselbach Equation falls cure for 2-3 weeks or longer (depending on the clinical condition of the patient); invasive procedures / surgery - initial dose at a rate of 90 mcg / kg administered immediately before intervention, the introduction of this repeat dose in 2 hours and then during the first 24-48 hours - 2-3 hours (depending on the amount of intervention and the clinical condition of the patient), with major surgery drug is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients who underwent Low Anterior Resection surgery, treatment for Years Old weeks before healing wounds; factor VII deficiency - a range dispatchering doses recommended for treatment of bleeding and Prevention in patients who have to conduct surgery or invasive procedures is 15-30 mg / kg every 4-6 hours to achieve hemostasis, the dose and dispatchering input picked individually; trombasteniya Whole Blood - dispatchering range of doses recommended for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg here dispatchering every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a slow infusion may be ineffective, treatment for trombasteniyi Hlantsmana patients in which no resistance should first enter platelets. Mr injection, 10 mg / ml to 1 ml in amp.